{"id":"papaveroline","rwe":[{"pmid":"39004678","year":"2025","title":"Computational Insights into Papaveroline as an In Silico Drug Candidate for Alzheimer's Disease via Fyn Tyrosine Kinase Inhibition.","finding":"","journal":"Molecular biotechnology","studyType":"Clinical Study"},{"pmid":"36838572","year":"2023","title":"Papaverinol-N-Oxide: A Microbial Biotransformation Product of Papaverine with Potential Antidiabetic and Antiobesity Activity Unveiled with In Silico Screening.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"18970084","year":"2005","title":"Development of an indirect competitive ELISA for the determination of papaverine.","finding":"","journal":"Talanta","studyType":"Clinical Study"},{"pmid":"15196583","year":"2004","title":"Getting new bronchodilator compounds from molecular topology.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"10978581","year":"2000","title":"Dopaminergic neurotoxins, 6,7-dihydroxy-1-(3', 4'-dihydroxybenzyl)-isoquinolines, cause different types of cell death in SH-SY5Y cells: apoptosis was induced by oxidized papaverolines and necrosis by reduced tetrahydropapaverolines.","finding":"","journal":"Neuroscience letters","studyType":"Clinical Study"}],"tags":[{"label":"papaveroline","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["papaveroline"],"offLabel":[],"synonyms":["papaveroline"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"papaveroline","explanation":"Imagine papaveroline as a key that fits into a lock on a cell. When it binds to this lock, it can affect the way the cell functions, potentially leading to changes in the body's response to certain conditions. However, the exact details of how papaveroline interacts with its target are still unclear.","oneSentence":"Papaveroline is thought to work by interacting with a specific cellular target, although its exact mechanism of action is not well understood.","technicalDetail":"Papaveroline's mechanism of action is believed to involve the inhibition of a specific enzyme or receptor, although further research is needed to confirm this hypothesis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2057","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PAPAVEROLINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:15:18.362308","biosimilars":[],"competitors":[],"genericName":"papaveroline","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"A0CR5J8X17","INN_ID":"3408","UMLSCUI":"C0070050","ChEMBL_ID":"CHEMBL351585","PUBCHEM_CID":"5459346","MESH_SUPPLEMENTAL_RECORD_UI":"C011054"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":17,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Jul","pmid":"39004678","title":"Computational Insights into Papaveroline as an In Silico Drug Candidate for Alzheimer's Disease via Fyn Tyrosine Kinase Inhibition.","journal":"Molecular biotechnology"},{"date":"2023 Feb 7","pmid":"36838572","title":"Papaverinol-N-Oxide: A Microbial Biotransformation Product of Papaverine with Potential Antidiabetic and Antiobesity Activity Unveiled with In Silico Screening.","journal":"Molecules (Basel, Switzerland)"},{"date":"2005 May 15","pmid":"18970084","title":"Development of an indirect competitive ELISA for the determination of papaverine.","journal":"Talanta"},{"date":"2004 Jul","pmid":"15196583","title":"Getting new bronchodilator compounds from molecular topology.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2000 Sep 15","pmid":"10978581","title":"Dopaminergic neurotoxins, 6,7-dihydroxy-1-(3', 4'-dihydroxybenzyl)-isoquinolines, cause different types of cell death in SH-SY5Y cells: apoptosis was induced by oxidized papaverolines and necrosis by reduced tetrahydropapaverolines.","journal":"Neuroscience letters"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"PAPAVEROLINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Papaveroline is a small molecule drug in the papaveroline class, but its target and mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. Papaveroline's indications, half-life, bioavailability, generic manufacturers, and patent status are also unknown. As a result, there is limited information available on its safety and efficacy. Further research is needed to understand its potential therapeutic applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}